TABLE 5 | Antibiotic resistance phenotype and genotype patterns.



<table><tr><td rowspan="2">Staphylococcus spp.</td><td rowspan="2">Resistance pattern</td><td rowspan="2">Number of antibiotics</td><td colspan="5">Resistance Genes</td></tr><tr><td>mecA</td><td>gyrA</td><td>grlA</td><td>gyrB</td><td>cfr</td></tr><tr><td rowspan="9">S. aureus (n = 9)</td><td>P, CN, E, DA, VA, SXT</td><td>6</td><td></td><td></td><td></td><td>+</td><td></td></tr><tr><td>P, OX, CN, DA, TE, DA, SXT, CIP</td><td>8</td><td></td><td>+</td><td>+</td><td></td><td></td></tr><tr><td>P, MET, CN, E, DA, TE, SXT, CIP</td><td>8</td><td>+</td><td></td><td>+</td><td></td><td></td></tr><tr><td>P, OX, CN, DA, TE, VA, SXT, CIP</td><td>8</td><td></td><td>+</td><td>+</td><td>+</td><td></td></tr><tr><td>P, OX, MET, CN, E, DA, TE, SXT, CIP</td><td>9</td><td></td><td>+</td><td>+</td><td></td><td></td></tr><tr><td>P, OX, MET, CN, E, DA, C, TE, VA, SXT, CIP</td><td>11</td><td>+</td><td>+</td><td>+</td><td></td><td></td></tr><tr><td>P, OX, MET, CN, E, DA, C, TE, VA, SXT, CIP</td><td>11</td><td>+</td><td>+</td><td>+</td><td></td><td></td></tr><tr><td>P, OX, MET, SAM, CN, E, DA, C, VA, SXT, CIP</td><td>11</td><td>+</td><td>+</td><td>+</td><td></td><td>+</td></tr><tr><td>P, OX, MET, SAM, CN, E, DA, C, TE, VA, SXT, CIP</td><td>12</td><td>+</td><td>+</td><td>+</td><td></td><td>+</td></tr><tr><td rowspan="10">S. hyicus (n = 10)</td><td>P, VA, SXT, CIP</td><td>4</td><td></td><td>+</td><td>+</td><td></td><td></td></tr><tr><td>CN, E, DA, C, TE, SXT</td><td>6</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P, OX, MET, CN, DA, SXT</td><td>6</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P, OX, MET, CN, DA, SXT</td><td>6</td><td></td><td></td><td></td><td>+</td><td></td></tr><tr><td>CN, DA, TE, VA, SXT, CIP</td><td>6</td><td></td><td>+</td><td>+</td><td></td><td></td></tr><tr><td>P, CN, DA, TE, VA, SXT, CIP</td><td>7</td><td></td><td>+</td><td>+</td><td></td><td></td></tr><tr><td>P, OX, CN, DA, VA, SXT, CIP</td><td>7</td><td></td><td>+</td><td>+</td><td></td><td></td></tr><tr><td>P, OX, MET, CN, DA, TE, VA, SXT</td><td>8</td><td>+</td><td></td><td></td><td></td><td></td></tr><tr><td>P, OX, MET, CN, DA, TE, VA, SXT, CIP</td><td>9</td><td>+</td><td>+</td><td>+</td><td>+</td><td></td></tr><tr><td>P, OX, MET, CN, DA, TE, VA, SXT, CIP</td><td>9</td><td>+</td><td>+</td><td>+</td><td>+</td><td></td></tr><tr><td rowspan="3">S. intermedius (n = 3)</td><td>P, OX, CN, DA, VA, SXT</td><td>6</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P, OX, CN, E, DA, TE, VA, SXT, CIP</td><td>9</td><td></td><td>+</td><td>+</td><td>+</td><td></td></tr><tr><td>P, OX, MET, CN, E, DA, VA, SXT, C, TE, CIP</td><td>11</td><td>+</td><td>+</td><td>+</td><td></td><td></td></tr><tr><td rowspan="4">S. schleiferi subsp. Coagulans (n = 4)</td><td>P, OX, MET, CN, DA, SXT, CIP</td><td>7</td><td></td><td>+</td><td>+</td><td></td><td></td></tr><tr><td>P, OX, MET, SAM, CN, DA, SXT</td><td>7</td><td></td><td></td><td>+</td><td>+</td><td></td></tr><tr><td>P, OX, MET, CN, E, DA, C, TE, VA, SXT</td><td>10</td><td>+</td><td></td><td></td><td></td><td></td></tr><tr><td>P, OX, MET, CN, E, DA, C, TE, VA, SXT</td><td>10</td><td>+</td><td></td><td></td><td></td><td></td></tr><tr><td>S. lentus (n = 1)</td><td>P, OX, MET, SAM, CN, E, DA, TE, VA, SXT, CIP</td><td>11</td><td></td><td>+</td><td>+</td><td></td><td></td></tr><tr><td>Total (n = 27)</td><td></td><td></td><td>11/27</td><td>17/27</td><td>19/27</td><td>7/27</td><td>2/27</td></tr></table>

C, Chloramphenicol; CIP, Ciprofloxacin; CN, Gentamycin; DA, Clindamycin; E, Erythromycin; MET, Methicillin; OX, Oxacillin; P, Penicillin; SAM, Ampicillin-sulbactam; SXT, Sulfamethoxazole/Trimethoprim; TE, Tetracycline; VA, Vancomycin.

(2010; Doyle et al., 2013) due to sample collection schemes, sample types, their minimum capability to implement AMR surveillance, rock-bottom financial and technical resources and differences in the implemented methodologies in the form of credibility, duplicability, enequitable significance, price, duration and simplicity (Strommenger et al., 2006; Cookson et al., 2007; Faria et al., 2008; Vindel et al., 2009; David et al., 2013) which makes any comparative effort to be unadvisable.

A wide dispersion of two categories of resistance has been revealed in the present investigation: 100% of our isolates carried the QRDRs responsible for quinolone resistance genes (gyrA and grlA) (17/27, 63% and 19/27, 70.4%) and the mecA resistance determinant (11/27, 40.7%), responsible for the methicillin and oxacillin resistance (Table 5). The mecA determinant has caused severe complications during the treatment MRSA in humans (Lee, 2003) and for S. epidermidis infections too (Kitao, 2003) when the hypothesis that, mecA is transferred from non-S. aureus staphylococci to S. aureus (Grundmann et al., 2006; Bhargava and Zhang, 2014) is taken into consideration.



The French National Monitoring Program (RESABO) established evidence that S. aureus is more susceptible to antimicrobial drugs than non-S. aureus species (Werckenthin et al., 2001). Conversely, our results had a commensurate regular and sequence discernible in the antibiotic resistance genes between S. aureus and non-S. aureus isolates. The results showed a congruity between phenotypic resistance and molecular genotyping for oxacillin, QRDRs, and PhLOPSA phenotypes. Generally, our results are in assonance with